I agree with this principle: he who prescribes takes the responsibility.
With drugs and procedures that require hospital skills or monitoring,
bouncing requests for primary care sponsorship of drugs is straight
forward.
However, with other drugs, and I include Hyalgon in this group, it is
not difficult for a GP to look up the details in ABPI manual, or talk to
the consultant who suggests the drug's use. I feel uneasy about
rejecting these drugs reflexly because a)the primary reason for doing so
is the expense of the drug and b)it suggests I am unable to learn
anything new.
What I think is most important with Hyalgon is that rheumatologists are
not convinced about its long term benefit. This would make me
disinclined to prescribe it.
In article <[log in to unmask]>, David Baker
<[log in to unmask]> writes
>As with any drug he who prescribes takes the responsibility. If as I
>suspect the GP knows little of this new wonder drug, it *must* be
>prescribed by the consultant not by the GP. If you are happy with the
>Hyalgon and know all about it it is a question of who funds the four shots
>- again it should be the consultant not the GP.
>
>David Baker
--
Paul J Scott, Primary Care Physician, United Kingdom.
Fax 44 (0)1935 410188
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|